SCHEDULE: Braeden Lichti Discloses 5.05% Stake in enVVeno Medical

Braeden Lichti and Northstrive Fund II LP have disclosed beneficial ownership of 5.05% of enVVeno Medical Corporation's common stock.

Summary

• Braeden Lichti and Northstrive Fund II LP reported beneficial ownership of enVVeno Medical Corporation common stock.
• Braeden Lichti beneficially owns 33,151 shares, representing 5.05% of the class.
• Northstrive Fund II LP beneficially owns 20,129 shares, representing 3.07% of the class.
• Mr. Lichti is the Manager of Northstrive Fund II LP.
• The ownership percentages are based on 655,606 shares of common stock outstanding as of January 20, 2026, as reported by the Issuer on a Form 8-K.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant beneficial ownership disclosure by an individual and an investment fund suggests confidence in enVVeno Medical Corporation's value proposition, albeit as a passive investment.

Positives

• A significant beneficial ownership stake by Braeden Lichti, exceeding the 5% threshold, indicates a notable investment in enVVeno Medical Corporation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment stake, typically by institutional investors or individuals, suggesting confidence in the company's long-term prospects without seeking control. This type of disclosure is common for investors accumulating significant positions in publicly traded medical device companies like enVVeno Medical.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially signaling investor confidence.

Key Dates

Recommendation

The filing indicates a significant, passive investment by Braeden Lichti and Northstrive Fund II LP, suggesting confidence in enVVeno Medical Corporation. While this is a positive signal, a Schedule 13G does not provide operational or financial performance data to warrant a 'buy' recommendation. Investors should 'hold' and monitor future company performance and any further disclosures from these beneficial owners.

Keywords

enVVeno Medical Corporation, Braeden Lichti, Northstrive Fund II LP, Schedule 13G, beneficial ownership, common stock, equity stake, institutional investment, SEC filing